Article

Treatment discontinuation in atypical hemolytic uremic syndrome (aHUS): A qualitative study of international experts’ perspectives with associated cost-consequence analysis

2024-04-23

Abstract excerpt

<title>Abstract</title> <p>Background Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA) related to congenital mutations impeding control of the alternative pathway of complement. Following approval of the complement C5 inhibitor eculizumab by the European Medicines Agency and the US Food and Drug Administration, initial guidelines suggested lifelong therapy. Y...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 629ea4f8-d512-5153-9ea2-6eb838698e00
DOI: 10.21203/rs.3.rs-4277648/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Treatment discontinuation in atypical hemolytic uremic syndrome (aHUS): A qualitative study of international experts’ perspectives with associated cost-consequence analysisDOI 10.21203/rs.3.rs-4277648/v1Read

[Clinical analysis of eculizumab in the treatment of atypical hemolytic uremic syndrome in children].Semantic proximity Read

Annual trends in atypical haemolytic uremic syndrome management in Japan and factors influencing early diagnosis and treatment: a retrospective studySemantic proximity Read

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.Semantic proximity Read

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.Semantic proximity Read

The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosisSemantic proximity Read

Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis.Semantic proximity Read

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus documentSemantic proximity Read

Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?Semantic proximity Read

Four-Year Report on Renal Outcomes Following Elective Withdrawal of Long-Term RAAS Blockade in a Cohort of Patients with Otherwise Inexplicable New-Onset and Progressive Acute Kidney InjurySemantic proximity Read

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysisSemantic proximity Read

Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeSemantic proximity Read

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.Semantic proximity Read